February 14, 2020 / 7:17 AM / 6 days ago

BRIEF-Immunovia Q4 Operating Loss Widens To SEK 29.6 Million

Feb 14 (Reuters) - Immunovia AB (publ):

* Q4 NET SALES SEK 45,000 VERSUS SEK 91,000 YEAR AGO

* Q4 OPERATING LOSS SEK 29.6 MILLION VERSUS LOSS SEK 25.7 MILLION YEAR AGO

* WE REMAIN FOCUSED ON INTRODUCING OUR BLOOD-BASED TEST TO MARKET IN Q3 2020

* WITH TWO MILESTONES REMAINING BEFORE COMMERCIALIZATION OF IMMRAY TECHNOLOGY IN Q3 2020, WE ARE INTENSIFYING FINAL LAUNCH PREPARATIONS

* WE WILL MARKET IMMRAY PANCAN-D FIRST IN USA AND THEN IN EUROPE

* WE CONTINUE TO INCREASE SPEED OF OUR COMMERCIALIZATION EFFORTS FOR A SUCCESSFUL LAUNCH OF IMMRAY PANCAN-D Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below